CD4 and HIV infectious disease: We formulated xfR5-D+T NPs, a CCR5 receptor targeting ARV-loaded nanoformulation with the potential to block HIV entrance and promote cellular immunity against HIV infection, specifically in memory CD4+ T-cells as they commit themselves to provide antiviral immunity as latent HIV reservoir [34].